| Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. | |
| | |
MedLine Citation:
|
PMID: 11786115 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: It is thought that transforming growth factor-beta1 (TGF-beta1) might be a key inhibitor of atherogenesis in non-uremic patients. We evaluated the intra- and post-dialytic serum levels of TGF-beta1 in uremic patients to assess if TGF-beta1 is an independent risk factor for cardiovascular diseases, and if any correlation exists between TGF-beta1 and any yet known atherosclerotic risk factors. METHODS: We studied 155 patients who were on regular hemodialysis, with or without clinically significant atherosclerotic vascular disease. Forty-one apparently healthy people were enrolled as a control group. TGF-beta1 was evaluated during the midweek dialysis session, at times 0, 30, and 120 minues, at the end of the session, and 3 hours after the session's end. All hitherto known atherosclerotic risk factors also were evaluated. The investigation was performed over a 24-month follow-up. RESULTS: TGF-beta1 values (mean +/- SD) in dialysis patients were 26.64 +/- 7.0 ng/mL (N=155) compared with 42.31 +/- 6.0 ng/mL in the control group (N=41, P < 0.0001). A weak inverse correlation emerged between TGF-beta1 and age (r=-0.28), TGF-beta1 and lipoprotein(a) [Lp(a); r=-0.35], TGF-beta1 and C-reactive protein (CRP; r=-0.27), and TGF-beta1 and plasminogen activator inhibitor-1 (PAI-1; r=-0.41). TGF-beta1 also correlated with albumin (r=0.31). In the coronary heart disease (CHD) group (N=32) the TGF-beta1 was 26.2 +/- 4.9 ng/mL; in the cerebrovascular disease (CVD) group (N=8) it was 26.7 +/- 3.7 ng/mL and in the peripheral vascular disease (PVD) group (N=9) it was 25.4 +/- 1.7 ng/mL. In dialysis patients with no cardiovascular disease (N=80) TGF-beta1 was 35.1 +/- 6.8 ng/mL (P < 0.0001 vs. CHD, CVD and PVD patients). TGF-beta1 was significantly lower among those patients with triple coronary vessel disease than with the other CHD patients. The Cox analysis demonstrated that a 1 ng/mL reduction in TGF-beta1 concentration was associated with a 9% increase in the relative risk of a cardiovascular event. CONCLUSIONS: TGF-beta1 was significantly reduced in hemodialysis patients, in particular in those with severe cardiovascular disease. Baseline TGF-beta1, diabetes mellitus and serum albumin levels proved to be the only independent contributors to atherosclerotic risk in dialysis patients. |
| | |
Authors:
|
Sergio Stefoni; Giuseppe Cianciolo; Gabriele Donati; Ada Dormi; Maria Grazia Silvestri; Luigi Colì; Antonio De Pascalis; Sandra Iannelli |
Related Documents
:
|
6166315 - Very low maternal plasma alpha-fetoprotein concentration. an indication for follow-up. 8917025 - Endothelial cell activity varies in patients at risk for the adult respiratory distress... 20507945 - Characterization of connective tissue disease-associated pulmonary arterial hypertensio... 18459085 - Short-term changes in hscrp and nt-probnp levels in hypertensive emergencies. 6689965 - The balloon proctogram. 22721885 - Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Kidney international Volume: 61 ISSN: 0085-2538 ISO Abbreviation: Kidney Int. Publication Date: 2002 Jan |
Date Detail:
|
Created Date: 2002-01-11 Completed Date: 2002-03-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0323470 Medline TA: Kidney Int Country: United States |
Other Details:
|
Languages: eng Pagination: 324-35 Citation Subset: IM |
Affiliation:
|
Nephrology Dialysis and Renal Transplantation Unit, Department of Clinical Medicine and Applied Biotechnology, S. Orsola University Hospital, Bologna, Italy. sstefoni@almans.unibo.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Coronary Artery Disease / blood*, mortality* Female Follow-Up Studies Genotype Humans Kidney Failure, Chronic / blood*, mortality*, therapy Logistic Models Male Middle Aged Myocardial Ischemia / blood, mortality Predictive Value of Tests Renal Dialysis Risk Factors Survival Analysis Transforming Growth Factor beta / blood*, genetics Transforming Growth Factor beta1 Uremia / blood, mortality, therapy |
| Chemical | |
Reg. No./Substance:
|
0/TGFB1 protein, human; 0/Transforming Growth Factor beta; 0/Transforming Growth Factor beta1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Urea volume of distribution exceeds total body water in patients with acute renal failure.
Next Document: Quantifying porphobilinogen deaminase mRNA in microdissected nephron segments by a modified RT-PCR.